Related Experiment Video
Updated: Mar 9, 2026

Ultrasound Assessment of Flow-Mediated Dilation of the Brachial and Superficial Femoral Arteries in Rats
Published on: November 3, 2016
Intra- and interday reproducibility of high-flow-mediated constriction response in young adults
Joseph D Ostrem1,2, Nicholas G Evanoff1, Justin R Ryder3
1Laboratory of Integrative Human Physiology, School of Kinesiology, University of Minnesota, Minneapolis, MN, USA.
Background:
Previously, we have demonstrated that high-flow-mediated constriction (H-FMC) of the brachial artery has been shown to negatively affect flow-mediated dilation (FMD). However, the reproducibility of an H-FMC response is unknown.
Objective:
The aim of this study was to determine the intra- and interday reproducibility of H-FMC in young adults.
Methods:
Thirty young adults (15 male, 15 female; 24 ± 3 years) were assessed for H-FMC reproducibility via high-resolution ultrasound imaging of the brachial artery during and after forearm occlusion of a normal FMD procedure. Two vascular assessments were conducted for all participants during two separate visits with a minimum of 7 days in between. H-FMC was characterized as the greatest 10-s average constriction occurring after 3-s postocclusion compared to baseline brachial artery diameter and considered present if the percent change was <-0·1%.
Results:
Of the 120 total vascular assessments performed in this study, 98 of the assessments (80·3%) displayed an H-FMC. H-FMC diameter was not statistically different for intraday comparisons for visit 1 (P = 0·39) or visit 2 (P = 0·55) or interday comparisons between the first (P = 0·61) or second (P = 0·10) assessments. H-FMC percentage was also not statistically different for intra-day comparison for visit 1 (P = 0·94) or visit 2 (P = 0·15) or interday comparisons between the first (P = 0·63) or second (P = 0·16) assessments.
Conclusion:
These data are supportive of H-FMC being reproducible in young adults and included in future FMD studies. The impact of H-FMC on future CVD risk and development warrants evaluation.

